International Study of Comparative Health Effectiveness with Medical and Invasive Approaches–Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design - 17/12/18
, David J. Maron, MD b, Jerome L. Fleg, MD c, Sean M. O’Brien, MD d, Charles A. Herzog, MD e, Gregg W. Stone, MD f, Daniel B. Mark, MD, MPH d, John A. Spertus, MD, MPH g, Karen P. Alexander, MD d, Mandeep S. Sidhu, MD h, Glenn M. Chertow, MD b, William E. Boden, MD i, Judith S. Hochman, MD aon behalf of the ISCHEMIA-CKD Research Group
Riassunto |
Background |
Patients with chronic kidney disease (CKD) and stable ischemic heart disease are at markedly increased risk of cardiovascular events. Prior trials comparing a strategy of optimal medical therapy (OMT) with or without revascularization have largely excluded patients with advanced CKD. Whether a routine invasive approach when compared with a conservative strategy is beneficial in such patients is unknown.
Methods |
ISCHEMIA-CKD is a National Heart, Lung, and Blood Institute–funded randomized trial designed to determine the comparative effectiveness of an initial invasive strategy (cardiac catheterization and optimal revascularization [percutaneous coronary intervention or coronary artery bypass graft surgery, if suitable] plus OMT) versus a conservative strategy (OMT alone, with cardiac catheterization and revascularization [percutaneous coronary intervention or coronary artery bypass graft surgery, if suitable] reserved for failure of OMT) on long-term clinical outcomes in 777 patients with advanced CKD (defined as those with estimated glomerular filtration rate <30 mL/min/1.73m2 or on dialysis) and moderate or severe ischemia on stress testing. Participants were randomized in a 1:1 fashion to the invasive or a conservative strategy. The primary end point is a composite of death or nonfatal myocardial infarction. Major secondary endpoints are a composite of death, nonfatal myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, or resuscitated cardiac arrest; angina control; and disease-specific quality of life. Safety outcomes such as initiation of maintenance dialysis and a composite of initiation of maintenance dialysis or death will be reported. The trial is projected to have 80% power to detect a 22% to 24% reduction in the primary composite end point with the invasive strategy when compared with the conservative strategy.
Conclusions |
ISCHEMIA-CKD will determine whether an initial invasive management strategy improves clinical outcomes when added to OMT in patients with advanced CKD and stable ischemic heart disease.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Michelle O'Shaughnessy, MD, served as guest editor for this article. |
|
| RCT# NCT01985360. |
|
| Funding source: The study was funded by the National Heart, Lung, and Blood Institute (U01HL117904, U01HL117905). |
|
| Disclaimer: The content of this manuscript is solely the responsibility of the authors and does not necessarily reflect the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the United States Department of Health and Human Services. |
Vol 205
P. 42-52 - Novembre 2018 Ritorno al numero
Articolo precedente
- Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial
- Michael J. Mack, William T. Abraham, JoAnn Lindenfeld, Steven F. Bolling, Ted E. Feldman, Paul A. Grayburn, Samir R. Kapadia, Patrick M. McCarthy, D. Scott Lim, James E. Udelson, Michael R. Zile, James S. Gammie, A. Marc Gillinov, Donald D. Glower, David A. Heimansohn, Rakesh M. Suri, Jeffrey T. Ellis, Yu Shu, Saibal Kar, Neil J. Weissman, Gregg W. Stone
- Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
- Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. Dangas
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?